11 Apr. 2019
SUCCESSFUL 11TH BERLIN CONFERENCE
BEAM Alliance and BioCom co-organized the 11th Berlin Conference on Novel Antimicrobials & AMR Diagnostics, which was a great success. The meeting...
11 Apr. 2019
11 Apr. 2019
WHO’S FIRST GLASS (GLOBAL ANTIMICROBIAL SURVEILLANCE SYSTEM) RELEASE
WHO’s first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in bot...
11 Apr. 2019
DRIVE-AB ISSUES FINAL REPORT ON ITS RESEARCH-BASED SUGGESTIONS FOR DRIVING ANTIBIOTIC DEVELOPMENT WHILE ENSURING ACCESS AND SUSTAINABLE USE
Revitalising the Antibiotic pipeline: http://drive-ab.eu/news/drive-ab-report/
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
